Tech Company Financing Transactions

Akouos Funding Round

Pivotal Ventures, 5AM Ventures and Cormorant Asset Management participated in a $105 million Series B funding round for Akouos. This venture round was recorded on 3/4/2020.

Transaction Overview

Company Name
Akouos
Announced On
3/4/2020
Transaction Type
Venture Equity
Amount
$105,000,000
Round
Series B
Investors

Pivotal Ventures (Lead Investor)

5AM Ventures (Kush Parmar)

Cormorant Asset Management

Cowen Capital Partners

EcoR1 Capital Management

Fidelity Management & Research Company

New Enterprise Associates (Ed Mathers)

Novartis Venture Fund

Partners Innovation Fund

Polaris Partners

RA Capital

Sofinnova Ventures

Surveyor Capital

Wu Capital

Proceeds Purpose
Proceeds from the Series B will be used to advance Akouos's lead program, AK-OTOF, to first-in-human clinical studies subject to IND filing and acceptance, establish the company's in-house GMP manufacturing capabilities at its new offices in the Boston Seaport, accelerate the development of multiple pipeline programs that address other forms of sensorineural hearing loss with well-defined mechanisms and/or gene targets, and expand its team across research, clinical development and manufacturing.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
645 Summer St. 200
Boston, MA 02210
USA
Phone
(413) 949-3700
Website
www.akouos.com
Email Address
[email protected]
Overview
Akouos (Nasdaq: AKUS) is developing targeted therapies to restore and preserve hearing in genetically-defined patient populations.
Profile
Akouos LinkedIn Company Profile
Social Media
Akouos Company Twitter Account
Company News
Akouos News
Facebook
Akouos on Facebook
YouTube
Akouos on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Emmanuel Simons
  Emmanuel Simons LinkedIn Profile  Emmanuel Simons Twitter Account  Emmanuel Simons News  Emmanuel Simons on Facebook
Chief Medical Officer
Michael McKenna
  Michael McKenna LinkedIn Profile  Michael McKenna Twitter Account  Michael McKenna News  Michael McKenna on Facebook
Chief Scientific Officer
Gregory Robinson
  Gregory Robinson LinkedIn Profile  Gregory Robinson Twitter Account  Gregory Robinson News  Gregory Robinson on Facebook
VP - Bus. Development
Morgan Molloy
  Morgan Molloy LinkedIn Profile  Morgan Molloy Twitter Account  Morgan Molloy News  Morgan Molloy on Facebook
VP - Bus. Development
Rabia Ozden
  Rabia Ozden LinkedIn Profile  Rabia Ozden Twitter Account  Rabia Ozden News  Rabia Ozden on Facebook
VP - Finance
Aninda Katragadda
  Aninda Katragadda LinkedIn Profile  Aninda Katragadda Twitter Account  Aninda Katragadda News  Aninda Katragadda on Facebook
VP - General Counsel
Karoline Shair
  Karoline Shair LinkedIn Profile  Karoline Shair Twitter Account  Karoline Shair News  Karoline Shair on Facebook
VP - Human Resources
Steve Burke
  Steve Burke LinkedIn Profile  Steve Burke Twitter Account  Steve Burke News  Steve Burke on Facebook
VP - Product Management
John Connelly
  John Connelly LinkedIn Profile  John Connelly Twitter Account  John Connelly News  John Connelly on Facebook
VP - Regulatory Affairs
Jennifer Wellman
  Jennifer Wellman LinkedIn Profile  Jennifer Wellman Twitter Account  Jennifer Wellman News  Jennifer Wellman on Facebook

 

 

Browse more venture capital transactions:

Prev: 3/4/2020: Mize venture capital transaction
Next: 3/5/2020: Eden venture capital transaction

 

Share this article

 

Where The Data Comes From

We record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.